Use of human small leucine zipper protein in adipocyte differentiation procedure

• US 10,058,586 B2
• Filed: 08/31/2017
• Issued: 08/28/2018
• Est. Priority Date: 04/30/2013
• Status: Active Grant

• Current Assignee: Korea University Research and Business Foundation (Korea University)
• Original Assignee: Korea University Research and Business Foundation (Korea University)
• Inventors: Ko, Je Sang, Kim, Jeong-Han
• Primary Examiner(s): Alstrum Acevedo, James Henry
• Assistant Examiner(s): Martinez, Tara L
• Application Number:
  US15/692,789
• Publication Number:
  US 20180092962A1
• Time in Patent Office: 362 Days
• Field of Search: None
• CPC Class Codes: A61K 38/17 from animals; from humans enzyme inhibitors A61K38/005
• CPC Class Codes: C12N 2501/998 Proteins not provided for elsewhere
• CPC Class Codes: C12N 2506/1346 from mesenchymal stem cells
• CPC Class Codes: C12N 2506/1353 from bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0653 Adipocytes; Adipose tissue
• CPC Class Codes: C12Q 1/686 Polymerase chain reaction [PCR]
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 2500/10 involving cells
• CPC Class Codes: G01N 2800/042 Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
• CPC Class Codes: G01N 2800/044 Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
• CPC Class Codes: G01N 33/502 for testing non-proliferative effects

Abstract

The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPARγ2 to induce the formation of a complex of HDAC3 and PPARγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPARγ2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.

Claims

1. A screening method of a medicine for preventing or treating obesity, comprising:

contacting a cell transformed with human small leucine-zipper proteins (sLZIP) and Peroxisome proliferator-activated receptor γ

2 (PPARγ

2) with a candidate material, wherein either the human sLZIP or PPARγ

2 is coupled to a detectable component; and

detecting an increase in formation of the complex of the human small leucine-zipper proteins sLZIP and PPARγ

2 in the cell, whereby said candidate material is determined to be a material capable of preventing or treating obesity.

2. The screening method of claim 1, wherein the cell is an animal cell.

3. The screening method of claim 1, wherein the detectable component is selected from the group consisting of a fluorescent protein, Glutathione S transferase (GST), Flag-tag, Myc-tag and HA-tag.

4. The screening method of claim 1, wherein detecting is carried out by a reaction using the detectable component, or the human sLZIP or PPARγ

2-specific antibody.